RxDoctor Payments Data

Elizabeth Elliott

Psychiatric/Mental Health · Phoenix, AZNPI 1275699662

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $230,184 of the $362,732 with a category attached, or 63.5%. Neurocrine Biosciences, Inc. accounts for 96.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $118,834, more than ten times the $522 reported in 2021. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$362,732in general payments, 2019–2025

Across 518 payments — averaging $700.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$351K
  • Otsuka America Pharmaceutical, Inc.$9K
  • Solventum Corporation$2K
  • Avanir Pharmaceuticals, Inc.$1K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$125
  • Acadia Pharmaceuticals Inc$111

What the payments were for

  • Consulting fees$63,37617%
  • Speaking & faculty fees$230,18463%
  • Travel & lodging$57,66916%
  • Food & beverage$11,5033%
  • Education$20%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$362,732 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$71,057
NuedextaDextromethorphan Hbr/Quinidine74$57,377
Invega SustennaPaliperidone Palmitate19$54,360
RexultiBrexpiprazole43$31,124
VraylarCariprazine Hcl16$11,395
Divalproex Sodium86$9,122
Quetiapine Fumarate76$3,258
LoxapineLoxapine Succinate34$3,022
Olanzapine OdtOlanzapine11$2,631
Lurasidone Hcl33$2,276
Olanzapine35$1,800
Duloxetine Hcl29$1,243
Escitalopram Oxalate60$1,232
Sertraline Hcl48$1,007
Hydroxyzine Hcl37$966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$350,680$71,05718 claims
Avanir Pharmaceuticals, Inc.Nuedexta$1,067$57,37774 claims
Otsuka America Pharmaceutical, Inc.Rexulti$9,136$31,12443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →